Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses JM Jaynes, R Sable, M Ronzetti, W Bautista, Z Knotts, ... Science translational medicine 12 (530), eaax6337, 2020 | 258 | 2020 |
Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration CY Ock, B Keam, S Kim, JS Lee, M Kim, TM Kim, YK Jeon, DW Kim, ... Clinical cancer research 22 (9), 2261-2270, 2016 | 247 | 2016 |
8-Hydroxydeoxyguanosine: not mere biomarker for oxidative stress, but remedy for oxidative stress-implicated gastrointestinal diseases. CY Ock, EH Kim, HJ Lee, KB Hahm, DJ Choi, MH Chung World J Gastroenterol 18 (4), 302-308, 2012 | 213 | 2012 |
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma CY Ock, S Kim, B Keam, M Kim, TM Kim, JH Kim, YK Jeon, JS Lee, ... Oncotarget 7 (13), 15901, 2016 | 155 | 2016 |
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers CY Ock, JE Hwang, B Keam, SB Kim, JJ Shim, HJ Jang, S Park, BH Sohn, ... Nature communications 8 (1), 1050, 2017 | 140 | 2017 |
Artificial intelligence–powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non–small-cell lung cancer S Park, CY Ock, H Kim, S Pereira, S Park, M Ma, S Choi, S Kim, S Shin, ... Journal of Clinical Oncology 40 (17), 1916-1928, 2022 | 133 | 2022 |
Combined mutation of Apc, Kras, and Tgfbr2 effectively drives metastasis of intestinal cancer E Sakai, M Nakayama, H Oshima, Y Kouyama, A Niida, S Fujii, A Ochiai, ... Cancer research 78 (5), 1334-1346, 2018 | 123 | 2018 |
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma CY Ock, S Kim, B Keam, S Kim, YO Ahn, EJ Chung, JH Kim, TM Kim, ... Oncotarget 8 (58), 97920, 2017 | 86 | 2017 |
Association of PD-L1 expression with tumor-infiltrating immune cells and mutation burden in high-grade neuroendocrine carcinoma of the lung HS Kim, JH Lee, SJ Nam, CY Ock, JW Moon, CW Yoo, GK Lee, JY Han Journal of Thoracic Oncology 13 (5), 636-648, 2018 | 82 | 2018 |
Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients J Koh, CY Ock, JW Kim, SK Nam, Y Kwak, S Yun, SH Ahn, DJ Park, ... Oncotarget 8 (16), 26356, 2017 | 81 | 2017 |
Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer CY Ock, KW Lee, JW Kim, JS Kim, TY Kim, KH Lee, SW Han, SA Im, ... Clinical Cancer Research 21 (11), 2520-2529, 2015 | 69 | 2015 |
The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: a meta-analysis R Kim, S Hahn, J Shin, CY Ock, M Kim, B Keam, TM Kim, DW Kim, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2016 | 64 | 2016 |
First-line Pembrolizumab versus Pembrolizumab plus chemotherapy versus chemotherapy alone in non–small-cell lung cancer: a systematic review and network meta-analysis R Kim, B Keam, S Hahn, CY Ock, M Kim, TM Kim, DW Kim, DS Heo Clinical lung cancer 20 (5), 331-338. e4, 2019 | 63 | 2019 |
Prognostic implication of antitumor immunity measured by the neutrophil–lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer CY Ock, AR Nam, J Lee, JH Bang, KH Lee, SW Han, TY Kim, SA Im, ... Gastric Cancer 20, 254-262, 2017 | 61 | 2017 |
An international real-world analysis of the efficacy and safety of lorlatinib through early or expanded access programs in patients with tyrosine kinase inhibitor–refractory … VW Zhu, YT Lin, DW Kim, HH Loong, M Nagasaka, H To, YLE Ang, ... Journal of Thoracic Oncology 15 (9), 1484-1496, 2020 | 58 | 2020 |
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation CY Ock, TM Kim, TB Won, JH Hah, DW Kim, CS Rhee, MW Sung The Korean Journal of Internal Medicine 31 (3), 570-578, 2016 | 55 | 2016 |
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer S Kim, JY Jang, J Koh, D Kwon, YA Kim, JC Paeng, CY Ock, B Keam, ... Journal of Experimental & Clinical Cancer Research 38, 1-14, 2019 | 53 | 2019 |
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma C Park, KJ Na, H Choi, CY Ock, S Ha, M Kim, S Park, B Keam, TM Kim, ... Theranostics 10 (23), 10838, 2020 | 52 | 2020 |
A novel approach for stress-induced gastritis based on paradoxical anti-oxidative and anti-inflammatory action of exogenous 8-hydroxydeoxyguanosine CY Ock, KS Hong, KS Choi, MH Chung, Y soo Kim, JH Kim, KB Hahm Biochemical pharmacology 81 (1), 111-122, 2011 | 52 | 2011 |
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer YJ Kim, B Keam, CY Ock, S Song, M Kim, SH Kim, KH Kim, JS Kim, ... Lung cancer 136, 122-128, 2019 | 51 | 2019 |